Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066415 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
A Phase 2 study of Treatment for Prevention of Chronic Migraine, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 667
- Enrollment target
- 20
- Study locations
NCT02066415 is a Phase 2 study of Treatment for Prevention of Chronic Migraine that has completed, run by Amgen. The registered enrollment target is 667 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT02066415, a Phase 2 study of Treatment for Prevention of Chronic Migraine, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 667 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Erenumab
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Newport Beach
- Research Site - San Francisco
- Research Site - Santa Monica
- Research Site - Sherman Oaks
- Research Site - Stanford
Florida
- Research Site - Jacksonville
- Research Site - Orlando
- Research Site - Palm Beach Gardens
- Research Site - West Palm Beach
Georgia
- Research Site - Atlanta
- Research Site - Decatur
Massachusetts
- Research Site - Watertown
- Research Site - Worcester
Michigan
- Research Site - Ann Arbor
- Research Site - Kalamazoo
Connecticut
- Research Site - Stamford
Indiana
- Research Site - Indianapolis
Maryland
- Research Site - Pikesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2014-03-05 |
| Est. Completion | 2016-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066415
The ClinicalTrials.gov registry entry for NCT02066415 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment for Prevention of Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02066415 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02066415 about?
NCT02066415 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention". To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
What is the current status of trial NCT02066415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 667 participants. The study started on 2014-03-05. Estimated completion is 2016-04-28.
What conditions does trial NCT02066415 study?
This clinical trial studies the following conditions: Treatment for Prevention of Chronic Migraine.
What interventions are being tested in trial NCT02066415?
The interventions under investigation include: Placebo (DRUG), Erenumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02066415?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02066415 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.